IL177007A0 - 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors - Google Patents
2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitorsInfo
- Publication number
- IL177007A0 IL177007A0 IL177007A IL17700706A IL177007A0 IL 177007 A0 IL177007 A0 IL 177007A0 IL 177007 A IL177007 A IL 177007A IL 17700706 A IL17700706 A IL 17700706A IL 177007 A0 IL177007 A0 IL 177007A0
- Authority
- IL
- Israel
- Prior art keywords
- thiazoles
- aryl
- amino
- substituted
- tyrosine kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54006404P | 2004-01-30 | 2004-01-30 | |
PCT/IB2005/000401 WO2005073225A1 (fr) | 2004-01-30 | 2005-01-28 | 2-(3-substitues aryle)amino-4-aryle-thiazoles en tant qu'inhibiteurs de tyrosine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
IL177007A0 true IL177007A0 (en) | 2006-12-10 |
Family
ID=34826177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL177007A IL177007A0 (en) | 2004-01-30 | 2006-07-20 | 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1711497A1 (fr) |
JP (1) | JP2007519711A (fr) |
KR (1) | KR20060129413A (fr) |
CN (1) | CN1934107A (fr) |
AU (1) | AU2005209485A1 (fr) |
BR (1) | BRPI0507271A (fr) |
CA (1) | CA2554925A1 (fr) |
IL (1) | IL177007A0 (fr) |
NO (1) | NO20063861L (fr) |
NZ (1) | NZ548884A (fr) |
WO (1) | WO2005073225A1 (fr) |
ZA (1) | ZA200606152B (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA200702445A1 (ru) | 2005-05-09 | 2008-04-28 | Ачиллион Фармасьютикалз, Инк. | Соединения тиазола и способы их применения |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
BRPI0710548B8 (pt) | 2006-04-20 | 2021-05-25 | Janssen Pharmaceutica Nv | inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica |
ES2389678T3 (es) * | 2006-04-20 | 2012-10-30 | Janssen Pharmaceutica Nv | Un inhibidor de la quinasa C-Kit para su uso en el tratamiento de tumores del estroma gastrointestinal o mastocitosis |
ATE510832T1 (de) | 2006-04-20 | 2011-06-15 | Janssen Pharmaceutica Nv | Heterocyclische verbindungen als c-fms- kinasehemmer |
WO2008080134A2 (fr) * | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles utiles en tant qu'inhibiteurs de axl |
GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
JP2010528019A (ja) | 2007-05-22 | 2010-08-19 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ヘテロアリール置換チアゾール |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
US20110105436A1 (en) * | 2008-03-10 | 2011-05-05 | Auckland Uniservices Limited | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
PT2387395E (pt) | 2009-01-16 | 2015-02-04 | Rigel Pharmaceuticals Inc | Inibidores de axl para utilização em terapia de combinação para prevenir, tratar ou gerir cancro metastático |
WO2013014170A1 (fr) * | 2011-07-27 | 2013-01-31 | Ab Science | Dérivés d'oxazole et de thiazole comme inhibiteurs sélectifs de protéines kinases (c-kit) |
CN103130792B (zh) * | 2011-11-30 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种2-氨基噻唑类化合物 |
EP2869897A4 (fr) * | 2012-07-06 | 2016-09-28 | Univ Duke | Activation du canal ionique trpv4 par stimuli physiques et rôle critique de trpv4 dans l'inflammation et la démangeaison spécifique à un organe |
AU2013299922B2 (en) | 2012-08-07 | 2018-06-21 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
CN103254184B (zh) * | 2013-05-27 | 2015-03-18 | 湖南科技大学 | 5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-三唑类化合物及其用途 |
CN103319467B (zh) * | 2013-06-15 | 2015-10-14 | 湖南科技大学 | 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途 |
WO2016028325A1 (fr) | 2014-08-22 | 2016-02-25 | Duke University | Inhibiteurs et de trpa1 de trpv4 et procédés pour les utiliser dans des cas d'inflammation et de prurit spécifique d'un organe |
US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
EP3439656A4 (fr) | 2016-04-07 | 2020-03-11 | Duke University | Inhibiteurs doubles à petites molécules de trpv4 et trpa1 pour la désinfection et l'anesthésie |
MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9815200A (pt) * | 1997-10-27 | 2001-10-16 | Agouron Pharma | Composto, composição farmacêutica e método de tratamento de uma doença ou distúrbio mediado pela inibição de cdk4 ou um complexo de cdk4/ciclina |
US6262096B1 (en) * | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
AU779089B2 (en) * | 1999-04-15 | 2005-01-06 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Cyclic protein tyrosine kinase inhibitors |
HN2002000156A (es) * | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
JP4388805B2 (ja) * | 2001-08-13 | 2009-12-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 2−アミノ−4,5−三置換チアゾリル誘導体 |
WO2003062215A1 (fr) * | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2 |
US20050239852A1 (en) * | 2002-08-02 | 2005-10-27 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
BRPI0410905A (pt) * | 2003-06-03 | 2006-06-27 | Novartis Ag | inibidores de p-38 |
-
2005
- 2005-01-28 KR KR1020067017411A patent/KR20060129413A/ko not_active Application Discontinuation
- 2005-01-28 AU AU2005209485A patent/AU2005209485A1/en not_active Abandoned
- 2005-01-28 CA CA002554925A patent/CA2554925A1/fr not_active Abandoned
- 2005-01-28 WO PCT/IB2005/000401 patent/WO2005073225A1/fr active Application Filing
- 2005-01-28 JP JP2006550363A patent/JP2007519711A/ja active Pending
- 2005-01-28 CN CNA2005800081898A patent/CN1934107A/zh active Pending
- 2005-01-28 NZ NZ548884A patent/NZ548884A/en unknown
- 2005-01-28 EP EP05702517A patent/EP1711497A1/fr not_active Withdrawn
- 2005-01-28 BR BRPI0507271-9A patent/BRPI0507271A/pt not_active IP Right Cessation
-
2006
- 2006-07-20 IL IL177007A patent/IL177007A0/en unknown
- 2006-07-25 ZA ZA200606152A patent/ZA200606152B/xx unknown
- 2006-08-30 NO NO20063861A patent/NO20063861L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20060129413A (ko) | 2006-12-15 |
NZ548884A (en) | 2010-06-25 |
EP1711497A1 (fr) | 2006-10-18 |
NO20063861L (no) | 2006-10-23 |
BRPI0507271A (pt) | 2007-06-26 |
JP2007519711A (ja) | 2007-07-19 |
AU2005209485A1 (en) | 2005-08-11 |
WO2005073225A1 (fr) | 2005-08-11 |
CA2554925A1 (fr) | 2005-08-11 |
CN1934107A (zh) | 2007-03-21 |
ZA200606152B (en) | 2007-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL177007A0 (en) | 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors | |
IL177278A0 (en) | Pyrazolotriazines as kinase inhibitors | |
IL186845A0 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
EP1794137A4 (fr) | Inhibiteurs de kinases specifiques | |
IL173200A0 (en) | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors | |
EP2040546A4 (fr) | Inhibiteurs de tyrosine kinase | |
AP2007003924A0 (en) | Imidazopyrazine as tyrosine kinase inhibitors | |
IL183276A0 (en) | Kinase inhibitors | |
EP1968950A4 (fr) | Inhibiteurs de pyrimidine kinase | |
HK1114380A1 (en) | Pyrrolopyrazoles as kinase inhibitors | |
IL173381A0 (en) | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
IL190078A0 (en) | Kinase inhibitors | |
IL181169A0 (en) | Trifluoromethyl substituted benzamides as kinase inhibitors | |
EP1951715A4 (fr) | Aminopyrimidines utiles en tant qu'inhibiteurs de kinases | |
ZA200900019B (en) | Tyrosine kinase inhibitors | |
EP1581539A4 (fr) | Nouveaux inhibiteurs de tyrosine kinase | |
HK1100141A1 (en) | Kinase inhibitors | |
EP1778693A4 (fr) | Composes heteroaryles tricycliques utiles en tant qu'inhibiteurs de kinase | |
PL1943243T3 (pl) | Inhibitory kinazy | |
EP1713793A4 (fr) | Derives de pyrimidinone utiles comme inhibiteurs de kinase | |
ZA200608775B (en) | Monocyclic heterocycles as kinase inhibitors | |
SI1896422T1 (sl) | Tirosin kinazni inhibitorji | |
EP1651599A4 (fr) | Inhibiteurs des tyrosine kinases | |
EP1951252A4 (fr) | Inhibiteurs des tyrosine kinases | |
IL184798A0 (en) | Quinazoline derivatives as tyrosine kinase inhibitors |